Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: Relationship with prognosis

Disease Markers

Volumn 20, Issue 6, 2004, Pages 333-343

  Ahmed, Maha Imam ^a   Salahy, Eman El ^a   Tawfiq, Hassan ^a   Khalifa, Ali ^a   Hassan, Manal M ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cervical carcinoma; Cervical neoplasms; Metalloproteinases; Polypeptide specific antigen; Recurrence

Indexed keywords

GELATINASE A; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL LYSATE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MICROPARTICLE ENZYME IMMUNOASSAY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RISK; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS; WESTERN BLOTTING;

HUMAN PAPILLOMA VIRUS; PAPILLOMAVIRUS;

EID: 15244350530     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/983243     Document Type: Article

References (49)

1. K.N. Gaarenstroom, G.G. Kenter, J.M. Bonfrer and C.M. Korse, Can initial Cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?, Gynecol. Oncol 77 (2000), 164-170.
2. L.A. Liotta, C.N. Rao and S.H. Barsky, Tumor invasion and the extracellular matrix, Lab. Invest 49 (1983), 636-649.
3. H.C. Crawford and L.N. Matrisian, Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression, Invasion Metastasis 14 (1994), 234-245.
4. S. Aznavoorian, A.N. Murphy, W.G. Stevenson and L.A. Liotta, Molecular aspects of tumor cell invasion and metastasis, Cancer 71 (1993), 1368-1383.
5. L.N. Matrrisian, The matrix-degrading metalloproteinases, Bioassays 14 (1992), 455-643.
6. L.A. Liotta and W.G. Stevenson, Tumor invasion and metastasis: an imbalance of positive and negative regulation, Cancer 51 (1991), 505-509.
7. G. Giannelli, C. Bergamini, F. Marinosci, E. Fransvea, M. Quaranta, L. Lupo, O. Schiraldi and S. Antonaciet, Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma, Int. J. Cancer 97 (2002), 425-431.
8. S. Curran and G.I. Murray, Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis, Eur. J. Cancer 36(13 Spec No) (2000), 1621-1630.
9. A.R. Nelson, B. Fingleton, M.L. Rothenberg and L.M. Matrisian, Matrix metalloproteinases: biologic activity and clinical implications, J. Clin. Oncol 18(5) (2000), 1135-1149.
10. W.G. Stevenson, P.D. Brown, M. Onisto, A.T. Levy and L.A. Liotta, Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues, J. Biol. Chem 265 (1990), 13933-13938.
11. G. Murphy and A.J.P. Docherty, The matrix metalloproteinase and their inhibitors, Am. J. Respir. Cell Mol. Biol 7 (1992), 120-125.
12. A.Y. Strongin, I. Collier, G. Bannikov, B.L. Mamer, G.A. Grant and G.I. Goldberg, Mechanism of cell surface activation of 72-KDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase, J. Biol. Chem 270 (1995), 5331-5338.
13. A. Talvensaari, M. Apaja-Sarkkinen, M. Hoyhtya, A. Westerlund, U. Puistola and T. Turpeenniemi, Matrix metalloproteinase-2 immunoreactive protein appears early in cervical dedifferentiation, Gynecol Oncol 72 (1999), 306-311.
14. G.J. Nuovo, P.B. Mac Connel, A. Simsir, F. Valea and D.L. French, Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma, Cancer Res 55 (1995), 251-267.
15. H. Kato and T. Torigoe, Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma, Cancer 40 (1977), 1621-1628.
16. G. Crombach, A. Scharl, M. Vierbuchen, H. Wurz and A. Bolte, Detection of squamous carcinoma antigen in normal squamous epithelia and in squamous cell carcinoma of the uterine cervix, Cancer 63 (1989), 1337-1342.
17. S. Catalteps, E. Gornstein, C. Schick, Y. Kamachi, K. Chatson, J. Fries, G. Silverman and M. Upton, Co-expression of squamous cell carcinoma antigen 1 and 2 in normal adult human tissues and squamous cell carcinoma, J. Histochem Cytochem 48 (2000), 113-122.
18. G. Crombach, H. Wurz, F. Herrmann, R. Kreienberg, V. Mobus, P. Schmidt-Rhode, G. Sturm, H. Caffier and H. Kaesemann, [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma, A cooperative study of the Gynecologic Tumor Marker Group (GTMG)], Dtsch. Med. Wochenschr 114 (1989), 700-705.
19. J.M. Bonfrer, E.M. Groeneveld, C.M. Korse, A. van Dalen, L.C. Oomen and D. Ivanyi, Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18, Tumour Biol 15 (1994), 210-222.
20. B. Bjorklund and R. Einarsson, TPS (tissue polypeptide specific antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer, Tumor Diagn. Ther 17 (1996), 67.
21. G. Banfi, A. Zebri, S. Pastori, D. Parolini, V. Carlo and P. Bonnini, Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer, Clin. Chem 39 (1993), 420-423.
22. M. Tarle, S. Grazio, I. Kraljic and K. Kovacic, A more objective staging of advanced prostate cancer routine recognition of malignant endocrine structure: Assessment of serum TPS PSA and NSE values, Prostate 24 (1994), 143-148.
23. G. Kornek, T. Schenk, M. Raderer, M. Djavarnmand and W. Scheithauer, Tissue polypeptide specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumors, Br. J. Cancer 71 (1995), 182-185.
24. Y.C. Hung, Y.C. Shiau, W.C. Chang, C.H. Kao and C.C. Lin, Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC), Neoplasma 49 (2002), 415-417.
25. S. Eissa and L. Seada, Quantitative of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry, Clin. Chem 44 (1998), 1423-1429.
26. M.M. Bradford, A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein dye binding, Anal. Biochem 62 (1967), 248-251.
27. R. Henderson, Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis, Ann. Clin. Biochem 30 (1993), 512-539.
28. A. Kramar, D. Faraggi, A. Fortune and B. Reiser, mROC: a computer program for combining tumour markers in predicting disease states, Computer Methods & Programs in Biomedicine 66 (2001), 199-207.
29. D.M. Parkin, F. Bray, J. Ferlay and P. Pisani, Estimating the world cancer burden: Globocan 2000, Int. J. Cancer 94 (2001), 153-106.
30. E.C. Turkistanli, N. Sogukpinar, B.K. Saydam and G. Aydemir, Cervical cancer prevention and early detection-the role of nurses and midwives, Asian Pac. J. Cancer Prev 4 (2003), 15-21.
31. N. Mokhtar, Cancer Pathology Registry [1989-1994]; National Cancer Institute: Bethesda, MD, Egypt, 1995.
32. C. Pyke, E. Ralfkiaer, K. Tryggvason and K. Dano, Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer, Am. J. Pathol 142 (1993), 359-365.
33. M.S. Naylor, G.W.H. Stamp, B. Davies and F.R. Balkwill, Expression and activity of MMPs and their regulators in ovarian cancer, Int. J. Cancer 58 (1994), 50-56.
34. M. Polette, N. Gilbert, I. Stas, B. Nawrocki, A. Noel, A. Remacle, W.G. Stetler-Stevenson, P. Birembaut and M. Foidart, Gelatinase expression and localization in human breast cancer. An in situ hybridization study and immunohistochemical detection using confocal microscopy, Virchows Arch 424 (1994), 641-645.
35. G.G. Garzetti, A. Ciavattini, G. Lucarini, G. Goteri, C. Romanini and G. Biagini, The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement, Gynecol. Oncol 60 (1996), 271-276.
36. B. Davidson, I. Goldberg, P. Liokumovich, J. Kopolovic, W.H. Gotlieb, L. Lerner-Geva, I. Reder and G. Ben-Baruch, Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix, Int. J. Gynecol. Pathol 17 (1998), 295-301.
37. B. Davidson, I. Goldberg, J. Kopolovic, L. Lerner-Geva, W. Gotlieb, G. Ben-Baruch and R. Reich, MMP-2 and TIMP-2 expression correlates with poor prognosis cervical carcinoma: A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization, Gynecol. Oncol 73 (1999), 372-382.
38. P.L. Moser, D.G. Kieback, L. Hfler, C. Tempfer, W. Neunteufel and G. Girsch, Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP) in stage IB cervical cancer, Anticancer Res 19 (1999), 4391-4393.
39. O. Brummer, G. Bohmer, B. Hollwitz, P. Flemming, K.U. Petry and H. Kuhnle, MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study, Gynecol. Oncol 84(2) (2002), 222-7222-7227.
40. M. Ueda, H. Fujii, K. Yoshizawa, Y. Terai, K. Kumagai, K. Ueki and M. Ueki, Effect of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells, Invasion Metastasis 18 (1998-1999), 176-183.
41. A. Ito, M. Yamada, T. Sato, M. Seiki, H. Nagase and Y. Mori, Calmodulin antagonists increase the expression of membrane-type-1 matrix metalloproteinase in human uterine cervical fibroblasts, Eur. J. Biochem 251 (1998), 453-458.
42. N. Chattopadhyay, A. Mitra, E. Fre and A. Chatterjee, Human cervical tumor cell (SiHa) surface integrin receptor has associated matrix metalloproteinase (MMP-2) activity, J Cancer Res. Clin. Oncol 127 (2001), 653-658.
43. M. Ueda, Y. Terai, Y. Yamashita, K. Kumagai, K. Ueki, H. Yamaguchi, D. Akise, Y.C. Hung and M. Ueki, Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas, Int. J. Cancer 98 (2002), 335-343.
44. C.Y. Zhou, J.F. Yao and X.D. Chen, [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1, 2 in human squamous cell carcinoma of uterine cervix], Ai Zheng 21 (2002), 735-739.
45. P.G. Rose, S. Baker and L. Serum, Squamous cell carcinoma antigen levels in invasive cervical carcinoma: prediction of response and recurrence, Am. J. Obest. Gynecol 168 (1993), 942-946.
46. I. Zakrzewska, The value of marker antigens TPS, SCC and CEA in diagnosis, evaluation of histologic type and clinical disease progression in patients with cervical carcinoma, Pol. Merkuriusz Lek 10 (2001), 21-23.
47. A. Sarandakou, I. Phocas, D. Botsis, K. Sikiotis, D. Rizos, D. Kalambokis, E. Trakakis and A. Chryssikopoulos, Tumor-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer, Eur. J. Gynecol. Oncol 19 (1998), 73-77.
48. J.L. Hecht, E.E. Sheets and K.R. Lee, Atypical glandular cells of undetermined significance in conventional cervical/vaginal smears and thin-layer preparations, Cancer 96 (2002), 1-4.
49. M.I. Ahmed, E.E. Salahy, S.T. Fayed, N.G. El-Hefnawy and A. Khalifa, Human papillomavirus infection among Egyptian females with cervical carcinoma: relationship to spontaneous apoptosis and TNF-alpha, Clinical Biochemistry 34 (2001), 491-498.